metoclopramide intravenous — Competitive Intelligence Brief

metoclopramide intravenous (metoclopramide intravenous) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine antagonist. Area: Gastroenterology.

phase 3 Dopamine antagonist D2 receptor Gastroenterology Small molecule

Target snapshot

metoclopramide intravenous (metoclopramide intravenous) — University Hospital, Bordeaux. Metoclopramide works by blocking dopamine receptors in the gastrointestinal tract, which helps to increase motility and relieve symptoms of gastroparesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
metoclopramide intravenous TARGET	metoclopramide intravenous	University Hospital, Bordeaux	phase 3	Dopamine antagonist	D2 receptor
IM aripiprazole once monthly	IM aripiprazole once monthly	University of Utah	marketed	Atypical antipsychotic	Dopamine D2 receptor, Dopamine D3 receptor
Aripiprazole/Escitalopram combination	Aripiprazole/Escitalopram combination	Massachusetts General Hospital	marketed	Atypical antipsychotic and selective serotonin reuptake inhibitor combination	Dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor (partial agonist), serotonin transporter (SERT inhibitor)
Latuda©	Latuda©	University of North Carolina, Chapel Hill	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT7 receptor, serotonin 5-HT1A receptor
Risperdal,reminyl	Risperdal,reminyl	Jinan Mental Hospital	marketed	Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl)	Dopamine D2 receptor, serotonin 5-HT2A receptor (Risperdal); Acetylcholinesterase (Reminyl)
ropinirole CR-RLS	ropinirole CR-RLS	GlaxoSmithKline	marketed	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
Aripiprazole or Perphenazine	Aripiprazole or Perphenazine	Johns Hopkins University	marketed	Atypical antipsychotic (aripiprazole); Typical antipsychotic (perphenazine)	Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); Dopamine D2 receptor (perphenazine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine antagonist class)

1. Benaroya Research Institute · 1 drug in this class
2. Dr. Reddy's Laboratories Limited · 1 drug in this class
3. Hospital de Clinicas de Porto Alegre · 1 drug in this class
4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class
5. University Hospital, Bordeaux · 1 drug in this class